Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Marian L. Burr, Christina E. Sparbier, Yih-Chih Chan et al. · Nature · 2017 · 950 citations · Full text

Medicine, Immunology, Oncology +12

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Daniel P. Bondeson, Blake E. Smith, George M. Burslem et al. · Cell chemical biology · 2017 · 901 citations · Full text

Engineering, Bioengineering, Biomolecular Engineering +13

Deubiquitination and Stabilization of PD-L1 by CSN5

Seung-Oe Lim, Chia‐Wei Li, Weiya Xia et al. · Cancer Cell · 2016 · 767 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +3

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · JAMA Oncology · 2020 · 436 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

Krzysztof M. Żak, P. Grudnik, Katarzyna Guzik et al. · Oncotarget · 2016 · 423 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17